FDA Draft guidance on Good ANDA Submission Practices [Regulatives / Guidelines]

posted by BRB  – Canada, 2018-01-03 22:42 (2661 d 09:49 ago) – Posting: # 18137
Views: 1,940

Hi all,

The FDA just posted a draft guidance on Good ANDA submission practices:

https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM591134.pdf


I found the section on deviations from product-specific guidances to be rather interesting such as:

A detailed justification for and data (such as their inclusion/exclusion criteria or demographic information) to support why their use of a particular study population does not affect their BE determination.

So for imatinib BE studies, which have been done in healthy subjects, but the guidance recommends to use patients, a detailed justification now needs to be provided?

BRB

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,711 registered users;
35 visitors (0 registered, 35 guests [including 9 identified bots]).
Forum time: 09:32 CEST (Europe/Vienna)

Do not worry about your difficulties in mathematics.
I can assure you mine are still greater.    Albert Einstein

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5